Press Releases

WASHINGTON, D.C., February 14, 2018 – The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 17, 2018 in New York City. This annual meeting provides institutional, strategic, and venture investors with unique insights into financing opportunities for cell and gene therapy-based treatments and tools.

WASHINGTON, D.C., January 30, 2018 – The Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute announced today the joint release of their recent study of medical director perspectives on value demonstration and reimbursement for regenerative and advanced therapies.

WASHINGTON, DC, January 18, 2018 – The Alliance for Regenerative Medicine (ARM) today announced its eighth annual Advanced Therapies Summit, to be held March 14, 2018 in Amsterdam, the Netherlands.

WASHINGTON, D.C., November 30, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapies and broader regenerative medicine sector, announced its 2018 Cell & Gene Therapies State of the Industry briefing will take place January 8, 2018 in San Francisco, held in conjunction with Biotech Showcase™ 2018.

WASHINGTON, D.C. – November 21, 2017 – The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter of 2017.

WASHINGTON, DC, November 16, 2017 – In response to the U.S. FDA’s announcement today regarding its regenerative medicine policy framework, the Alliance for Regenerative Medicine (ARM) has issued the following statement:

LONDON and WASHINGTON, D.C., October 17, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies Investor Day, to be held November 9, 2017 in London.

WASHINGTON, D.C., October 12, 2017 - In response to today’s FDA Advisory Committee’s 16-0 favorable review of Spark Therapeutics’ Luxturna, the Alliance for Regenerative Medicine has issued the following statement, attributable to Janet Lynch Lambert, CEO, ARM:

NEW YORK and WASHINGTON, D.C. October 5, 2017 – Today, Informa Pharma Intelligence and The Alliance for Regenerative Medicine (ARM), the preeminent global advocate for gene therapy, cell therapy and the broader regenerative medicine sector, announced an expansion to their partnership to advance awareness and understanding of regenerative medicine and its potentially transformative impact on healthcare and society.

WASHINGTON, D.C. October 4, 2017 – The Alliance for Regenerative Medicine (ARM), announced today the election of its 2018 Executive Committee and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.

Pages